Mayo Clinic
mayoclinic.orgTotal trials
3,202
Active
818
Phase 3
141
Total enrollment
13,282,079
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 326 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | 27 | ||||
| Semaglutide | — | — | — | — | 4 | ||
| Bupivacaine | — | — | — | — | 4 | ||
| Enfortumab Vedotin | — | — | — | — | 3 | ||
| Ketamine | — | — | 10 | ||||
| Oxycodone | — | — | — | 5 | |||
| Corticosteroid | — | — | — | — | — | 2 | |
| Low-Dose Aspirin | — | — | — | — | 2 | ||
| Acetaminophen | — | — | — | — | — | 2 | |
| Doxycycline | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | — | 2 | |
| Liposomal Bupivacaine | — | — | — | — | — | 6 | |
| Ropivacaine | — | — | — | 6 | |||
| Lisinopril | — | — | — | — | 3 | ||
| F-18 FDG | — | — | — | — | 3 | ||
| Dexmedetomidine | — | — | — | — | 2 | ||
| Methadone | — | — | — | — | 2 | ||
| Mepivacaine | — | — | — | — | 2 | ||
| Phentermine-Topiramate | — | — | — | — | 2 | ||
| 18-F-Flortaucipir | — | — | — | — | — | 1 | |
| Dextrose | — | — | — | — | — | 1 | |
| Clinisol 15% | — | — | — | — | — | 1 | |
| Itraconazole 200 mg | — | — | — | — | — | 1 | |
| Xylocaine | — | — | — | — | — | 1 | |
| Uroselective alpha-1-adrenergic receptor antagonist | — | — | — | — | — | 1 | |
| Ketamine Infustion | — | — | — | — | — | 1 | |
| Mavyret | — | — | — | — | — | 1 | |
| Low Sodium Oxybate | — | — | — | — | — | 1 | |
| Pittsburgh Compound B | — | — | — | — | — | 1 | |
| Tau | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide Low Dose | — | — | — | — | — | 1 | |
| Triamcinolone Acetonide Standard Dose | — | — | — | — | — | 1 | |
| Mycophenolate Mofetil (MMF) Maintenance Group | — | — | — | — | — | 1 | |
| Mycophenolate Mofetil (MMF) Withdrawal Group | — | — | — | — | — | 1 | |
| Dexamethasone IV | — | — | — | — | — | 1 | |
| Dexamethasone IV+Oral | — | — | — | — | — | 1 | |
| Dexamethasone IV+Oral 2 Day | — | — | — | — | — | 1 | |
| Oral Tranexamic Acid | — | — | — | — | — | 1 | |
| AV-1451 | — | — | — | — | — | 1 | |
| Cephalexin | — | — | — | — | — | 1 |
286 more active programs hidden
Next readouts
- 2021-03-26
- 2022-10-30
- 2023-08-29
- 2023-10-04
- 2024-01-31
- 2024-03-15
- 2024-07-16
- 2024-07-29
- 2024-07-30
- 2025-04-09
Top conditions
- Obesity87
- Healthy85
- Breast Cancer76
- Malignant Solid Neoplasm60
- Heart Failure41
- Breast Carcinoma33
- Atrial Fibrillation29
- Hematopoietic and Lymphatic System Neoplasm29
Frequently asked questions about Mayo Clinic
- How many clinical trials does Mayo Clinic have on ClinicalTrials.gov?
- Mayo Clinic is listed as the lead sponsor on 3,202 clinical trials in ClinicalTrials.gov, 818 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Mayo Clinic's trials are in Phase 3?
- 141 of Mayo Clinic's trials are in Phase 3, spread across 326 active drug programs.
- What therapeutic areas does Mayo Clinic focus on?
- Mayo Clinic's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Breast Cancer, Malignant Solid Neoplasm, Heart Failure.
- When are Mayo Clinic's next clinical trial readouts?
- Mayo Clinic has 10 upcoming primary-completion readouts tracked here; the soonest is “A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas”, expected around 2021-03-26.